Viking Therapeutics adds seasoned healthcare and digital health leader Dorothy Gemmell to its board of directors
Executive summary: Viking Therapeutics appointed Dorothy Gemmell to its board of directors. The appointment adds a director with extensive healthcare, digital health, and commercialization experience, bolstering board oversight of the company's commercialization strategy.
Who is involved: Viking Therapeutics (VKTX) and Dorothy Gemmell.
Likely next: Gemmell will participate in upcoming board meetings and contribute to oversight of clinical and commercial initiatives.
Viking Therapeutics announced the appointment of Dorothy Gemmell to its board, bringing over two decades of experience across healthcare, digital health, and commercialization. The move reinforces the company's focus on strengthening governance and commercial expertise as it advances its clinical-stage pipeline. The appointment was made public via a press release on July 23, 2026.
Timeline
- — Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors (PR Newswire)
- — VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio (GlobeNewswire)
Analysis — what this means
Sectors affected
- biopharmaceutical
- healthcare governance